WuXi AppTec Co., Ltd. Overview
Pro stress-test →WuXi AppTec provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in China, the United States, Europe, and internationally. As a mega-cap contract research organization, the company delivers end-to-end drug development solutions serving global pharmaceutical and biotech clients.
Strategic Profile
Pro stress-test →Operating through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments, the company offers CDRMO services for new drug development from discovery to commercial covering various synthetic molecular modalities including small molecules, oligonucleotides, peptides, and complex conjugates. The company derives key revenue from the United States of America, followed by China, Europe, and other regions.
Competitive Landscape
Pro stress-test →BGI Genomics, Pharmaron, HTG Molecular Diagnostics, Syngene International, and Molecular Cloning Laboratories are some of the 62 competitors of WuXi AppTec. WuXi AppTec maintains competitive advantage through integrated service offerings spanning chemistry, testing, and biology, combined with global scale and established client relationships across pharmaceutical and biotech sectors.
Industry Context
WuXi AppTec Co., Ltd. operates in Contract Research Organization (CRO) / Contract Development and Manufacturing Organization (CDMO).
Key facts
Founded: 2000 · Headquarters: Shanghai, China · Employees: 1,681 · Revenue: $6.15B · Market cap: $40.9B